How Effective are Gliflozins as DPP-4 Inhibitors? A Computational Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How Effective are Gliflozins as DPP-4 Inhibitors? A Computational Study
Authors
Keywords
-
Journal
THEORETICAL FOUNDATIONS OF CHEMICAL ENGINEERING
Volume 57, Issue 3, Pages 403-410
Publisher
Pleiades Publishing Ltd
Online
2023-09-05
DOI
10.1134/s0040579523030168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies
- (2021) Enrico Longato et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Structure based virtual screening of natural compounds and molecular dynamics simulation: Butirosin as Dipeptidyl peptidase (DPP-IV) inhibitor
- (2021) Rakesh Kumar Paul et al. Biocatalysis and Agricultural Biotechnology
- A Pilot Study of All-Computational Drug Design Protocol–From Structure Prediction to Interaction Analysis
- (2020) Yifei Wu et al. Frontiers in Chemistry
- Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study
- (2020) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
- (2020) Xiaohui Pan et al. Frontiers in Endocrinology
- Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
- (2019) Carolyn F. Deacon Frontiers in Endocrinology
- Class effect for SGLT-2 inhibitors: a tale of 9 drugs
- (2019) Dario Giugliano et al. Cardiovascular Diabetology
- Protein Preparation Automatic Protocol for High-Throughput Inverse Virtual Screening: Accelerating the Target Identification by Computational Methods
- (2019) Simona De Vita et al. Journal of Chemical Information and Modeling
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials
- (2018) Keke Wang et al. HORMONE AND METABOLIC RESEARCH
- Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- (2017) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Computational methods in drug discovery
- (2016) Sumudu P Leelananda et al. Beilstein Journal of Organic Chemistry
- Sedentary behaviour as a new behavioural target in the prevention and treatment of type 2 diabetes
- (2016) Joseph Henson et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
- (2016) André J. Scheen Expert Opinion on Drug Metabolism & Toxicology
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- DPP4 in diabetes
- (2015) Diana Röhrborn Frontiers in Immunology
- Adverse effects and safety of SGLT-2 inhibitors
- (2014) S. Halimi et al. DIABETES & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Computational Prediction of Drug Solubility in Fasted Simulated and Aspirated Human Intestinal Fluid
- (2014) Jonas H. Fagerberg et al. PHARMACEUTICAL RESEARCH
- Type 2 diabetes as a risk factor for cognitive impairment: current insights
- (2014) Hiroyuki Umegaki Clinical Interventions in Aging
- Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries
- (2013) L. M. Ruta et al. DIABETIC MEDICINE
- A Prospective Study of Weight Training and Risk of Type 2 Diabetes Mellitus in Men
- (2012) Anders Grøntved et al. ARCHIVES OF INTERNAL MEDICINE
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
- (2012) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
- (2011) R. M. Williamson et al. DIABETES CARE
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The incretin system and its role in type 2 diabetes mellitus
- (2008) J HOLST et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation
- (2008) William J. Metzler et al. PROTEIN SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search